(WO2019240865) Photosensitizers and method of treating cancer using the same 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(WO2019240865) Photosensitizers and method of treating cancer using the same
公开号/公开日
WO2019/240865 / 2019-12-19
申请号/申请日
WOUS2019/025103 / 2019-04-01
发明人
WU, Cheng-WenLIN, Erh-HsuanTSENG, Wan-Ting;
申请人
NANORAY BIOTECH;
主分类号
IPC分类号
A01N-043/00 A01N-043/04 A61K-031/70
摘要
(WO2019/240865) The present disclosure provides a heavy atom carrier arid a method of treating cancer using the heavy atom carriers in conjunction with monochromatic X-ray, The heavy atom carriers are halogen-containing heavy atom carriers.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
(WO2019240865) WANG, Chieh-Mei ([US])
代理机构
;
优先权号
2018US-62683009
主权利要求
(WO2019/240865) WHAT IS CLAIMED IS: 1. A method for treating cancer in a subject, comprising steps of:   a) administering a pharmaceutical composition comprising a therapeutically effective dosage of iododeoxyuridine (IdU) to the subject; and   b) irradiating a monochromatic X-ray to the subject. 2. The method according to claim 1, wherein the pharmaceutical composition further comprises a pharmaceutical carrier for facilitating absorption and distribution of IdU in the subject. 3. The method according to claim 1, wherein IdU is administered to the subject through a local route or a systemic route. 4. The method according to claim 3, wherein the local route is a topical route, an intratumoral injection, or an intravascular injection. 5. The method according to claim 3, wherein the systemic route is a gastrointestinal route, an intravenous injection, an intravenous drip infusion, an intramuscular injection, or a subcutaneous injection. 6. The method according to claim 1, wherein a radiation dose of the monochromatic X-ray irradiated to the subject is 1 Gy - 9 Gy. 7. The method according to claim 6, wherein the radiation dose of the monochromatic X-ray irradiated to the subject is 4.5 Gy or 9 Gy. 8. The method according to claim 1, wherein the therapeutically effective dosage is an injection amount of 3.75 mg - 62.5 mg. 9. The method according to claim 1 , wherein the therapeutically effective dosage is an injection volume of 7.5 ml - 125 ml. 10. A combination of a pharmaceutical composition comprising a therapeutically effective dosage of iododeoxyuridine (IdU) and a radiation dose of a monochromatic X-ray for use in the treatment of cancer. 11. The combination according to claim 10, wherein the pharmaceutical composition further comprises a pharmaceutical carrier for facilitating absorption and distribution of IdU in a subject. 12. The combination according to claim 10, wherein the radiation dose of the monochromatic X-ray is 1 Gy - 9 Gy. 13. The combination according to claim 12, wherein the radiation dose of the monochromatic X-ray is 4.5 Gy or 9 Gy. 14. The combination according to claim 10, wherein the therapeutically effective dosage is an injection amount of 3.75 mg - 62.5 mg. 15. The combination according to claim 10, wherein the therapeutically effective dosage is an injection volume of 7.5 ml - 125 ml. 16. A kit comprising:   a) a pharmaceutical composition comprising a therapeutically effective dosage of iododeoxyuridine (IdU); and   b) a monochromatic X-ray device. 17. The kit according to claim 16, wherein the pharmaceutical composition further comprises a pharmaceutical carrier for facilitating absorption and distribution of IdU in a subject. 18. The kit according to claim 16, wherein the therapeutically effective dosage is an injection amount of 3.75 mg - 62.5 mg. 19. The kit according to claim 16, wherein the therapeutically effective dosage is an injection volume of 7.5 ml - 125 ml. 20. The kit according to claim 16, wherein the monochromatic X-ray device has an energy of 33 keV. 21. A use of a combination of a pharmaceutical composition comprising a therapeutically effective dosage of iododeoxyuridine (IdU) and a radiation dose of a monochromatic X-ray for the manufacture of a medicament for the treatment of cancer. 22. The use according to claim 21, wherein the pharmaceutical composition further comprises a pharmaceutical carrier for facilitating absorption and distribution of IdU in a subject. 23. The use according to claim 21, wherein the radiation dose of the monochromatic X- ray is 1 Gy to 9 Gy. 24. The use according to claim 23, wherein the radiation dose of the monochromatic X- ray is 4.5 Gy or 9 Gy. 25. The use according to claim 21, wherein the therapeutically effective dosage is an injection amount of 3.75 mg - 62.5 mg. 26. The use according to claim 21, wherein the therapeutically effective dosage is an injection volume of 7.5 ml - 125 ml.
法律状态
PENDING
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部